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Table
Comparison of late aGVHD categories with classic aGVHD
De-novo
n¼7
Persistent
n¼39
Recurrent
n¼29
Classic
Acute
n¼268
Median time
to onset,
range
155 (101-262) 100 143 (102-342) 36 (7-180)
2 year overall
survival
after onset
(95% CI)
83% (27-97) 45% (28-60) 74% (53-87) 50% (44-57)
1 year NRM
after onset
0% 26% (12-40) 14% (4-26) 24% (19-29)
Progression
to cGVHD
within 2
years of
onset
42% (16-75) 51% (36-66) 38% (23-56) 31% (26-37)
Figure 2. Cumulative incidence of outcomes following late aGVHD
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S342received PBSC and 8% marrow as the graft source. 64%
received a reduced intensity conditioning. Median follow up
was 4 years.
Results: The cumulative incidence of any late aGVHD was
14.7% (95% CI: 11.6-17.8) and grade II-IV late aGVHD was
11.7% (95% CI 8.7-14.7) at one year (Figure 1). 52% had
persistent (deﬁned as active aGVHD that persisted without
resolution after 100 days), 39% had recurrent (aGVHD that
recurred following resolution after 100 days) and 9% had de-
novo late aGVHD. Median time to onset was 155 days for de-
novo late aGVHD, and 143 days for recurrent late aGVHD
(Table). Persistent late aGVHD was considered to have a time
of onset of 100 days. Outcomes were estimated from onset of
late aGVHD (Table). One and 2 year overall survival was 73%
(95% CI 63-84) and 59% (95% CI 49-72). Figure 2 shows the
cumulative incidences of outcomes after late aGVHD. Pro-
gression to cGVHD or overlap syndrome was seen in 45%
(95% CI 35-57) by two years. Durable discontinuation of
immunosuppression (IS) was achieved in 15%, 41% and 57% of
persistent, recurrent and de-novo late aGVHD. In multivar-
iate analysis, PBSC [HR 2.1, 95% CI: 1.2-3.5, p¼0.01] and
myeloablative conditioning [HR 1.8, 95% CI: 1.0-3.2, p¼0.04)]
were associated with higher risks of developing late aGVHD.
Conclusions: We present results of clinical presentation and
outcomes in patients with late aGVHD. Amongst patients
with late aGVHD, durable discontinuation of IS was seen in
only 15% of those with persistent late aGVHD, indicating
need for intensiﬁed therapy in this group. PBSC and mye-
loablative conditioning were associated with a higher risk of
developing late aGVHD. Modulation of these risk factors
(such as intensiﬁed or longer duration of GVHD prophylaxis
in these higher risk groups) may allow reduced risks and
improved transplant outcomes.Figure 1. Cumulative Incidence of Grade II-IV late aGVHD498
A Review of Radiographic Findings in GVHD
Michael Bernhard Osswald, Alexander W. Brown. Hematology/
Oncology, San Antonio Military Medical Center, JBSA-Fort Sam
Houston, TX
Acute and chronic graft vs host disease remains one of the
largest challenges in allogeneic stem cell transplantation.
Diagnosis and staging of GVHD is largely clinically based:
physical exam ﬁndings, laboratory data, combined with
pathologic conﬁrmation. Typical radiologic ﬁndingsmay aide
in diagnosis as well. Recent radiographs of GVHD patients are
reviewed. Notable ﬁndings in acute GVHD of the gut included
edematous bowel wall thickening and ﬂuid ﬁlled bowel.
Some patients have exhibited hyper enhancing gut mucosa
on contrast enhanced CT. PET scans may show diffuse
increased metabolic activity in affected areas. Chest CT
ﬁndings in chronic GVHD patients commonly include ground
glass opacities in the lungs, both peribronchial and para-
septal. Later advanced ﬁndings may classically include
bronchiectasis. MRI ﬁndings in sclerotic type GVHD may
include edema and enhancement within deep fascial planes.
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Cell
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Oncology, Instituto Nacional de Pediatría, Mexico, Mexico;
2 Instituto Nacional de Pediatría, Mexico, Mexico; 3 Instituto
Nacional de Pediatria, Mexico, Mexico
The acute graft versus host disease (aGVHD) is the most
common complication subsequent to allogeneic hematopoi-
etic progenitor cell donor match HLA (Human Leukocyte An-
tigen), occurring in 30-50%. In hematopoietic progenitor
transplantation (HSCT) there are other genetic factors such as
minor histocompatibility antigens and cytokines. The HLA-C
locus has been divided into two groups according to the amino
acid at position 80; this variation is important for the type of
KIR (killer cell Ig-like receptor). The C1 group contains a lysine
at position 80 and includes Cw2, -4 alleles -, - 5, -6, -15. The
group includes C2 Cw1, -3, -7, -8 alleles contains an asparagine
at position 80 alleles of the C1 group for KIR2DL1 and KIR2DS1
receptor and group C2 alleles bind to KIR2DL2 receptors bind
and KIR2DL3. The interaction of the different alleles of HLA-C
locus with KIR receptors expressed on NK cells cytotoxic ac-
tivity changes which inﬂuence the risk for development of
aGVHD.
Table
Patients with aGVH Patients without Agvh
Group C1
Cw2,-4,-5,-6,-15
(n9)
Group C2
Cw1,-3-7-8
(n23)
Cw4-Cw4 Cw3-Cw6
Cw4-Cw7 Cw3-Cw12
Cw3-Cw4 Cw3-Cw8
Cw4-Cw7 Cw3-Cw1
Cw4-Cw12 Cw3-Cw7
Cw6-Cw7 Cw3-Cw7
Cw1-Cw6 Cw3-Cw4
Cw2-Cw7 Cw7-Cw4
Cw7-Cw7 Cw4-Cw15
Cw7-Cw8
Cw3-Cw8
Cw3-Cw4
Cw6-Cw7
Cw3-Cw7
Cw6-Cw7
Cw1-Cw7
Cw7-Cw8
Cw3-Cw7
Cw4-Cw6
Cw6-Cw12
Cw3-Cw16
Cw4-Cw12
Cw1-Cw4
Figure. Ofatumumab therapy depletes total CD19+ B cells and IgG. *CD19+ B ce
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S343Our objective was to determine the association of poly-
morphisms of HLA-C locus with the risk of developing
aGVHD in pediatric HSCT patients.
All patients who underwent HSCT from an HLA identical
related donor in the period between January 2008 and
September 2013. HLA results that were taken as part of the
protocol for HSCT were analyzed. Descriptive statistics and
the difference between the groups that developed aGVHD
were performed with chi2, and the odds ratio (OR) was
calculated as a measure of association, is also the 95%
calculation.
Nine patients (28.12%) developed aGVHD and 8/9 patients
(88.9%) were carriers of an allele group HLA-C C1 OR 38; 95%
CI 3.7-395; p ¼ 0.0002. Of the 23 patients who did not
develop aGVHD,19 (82.6%) were carriers of at least one allele
of the group C2, RM 0.0263; 95% CI 0.0025 to 0.2735;
p ¼ 0.0002 (table 1).500
Ofatumumab in Combination with Glucocorticoids for
Primary Therapy of Chronic Graft Vs. Host Disease
Joseph Pidala 1, Jongphil Kim 2, Binglin Yue 2, Brian Betts 1,
Melissa Alsina 1, Ernesto Ayala 1, Hugo Fernandez 1,ll comparison (3mo vs. baseline): p¼0.02; all other comparisons: p¼NS.
